MiNK Therapeutics (NASDAQ:INKT) Issues Quarterly Earnings Results

MiNK Therapeutics (NASDAQ:INKT) issued its quarterly earnings data on Friday. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.20, Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK said its AGENT-797 iNKT platform continues to show encouraging signals across oncology and critical illness, including durable survival in refractory gastric cancer and immune modulation in ARDS and lung injury.
• The company initiated a randomized phase II ARDS trial of AGENT-797 versus placebo on top of standard of care, with a planned seamless phase II/III design and FDA discussions expected in the coming weeks.
• Management highlighted translational data showing the same donor-derived product can generate different immune responses depending on disease state, supporting a potential biomarker-driven approach for patient selection in ARDS.
• MiNK’s cash position of about $9.5 million at quarter-end, plus operational efficiencies and non-dilutive collaboration support, is expected to fund at least the next 12 months of operations, including the randomized trial launch.
• The company also expanded its pipeline and partnership strategy through a C-Further collaboration for a PRAME-targeted TCR-engineered iNKT program in pediatric cancers and said it will present additional data, including an ANKTIVA combination study, at upcoming medical meetings.

MiNK Therapeutics Stock Performance

Shares of INKT traded up $0.21 on Friday, reaching $10.72. The company’s stock had a trading volume of 36,280 shares, compared to its average volume of 39,440. MiNK Therapeutics has a 12-month low of $6.65 and a 12-month high of $76.00. The stock’s 50 day simple moving average is $11.00 and its two-hundred day simple moving average is $11.61.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on INKT shares. Weiss Ratings cut shares of MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of MiNK Therapeutics in a research report on Wednesday, April 1st. Finally, Wall Street Zen raised shares of MiNK Therapeutics to a “sell” rating in a research report on Saturday, April 25th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $35.00.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC purchased a new position in MiNK Therapeutics, Inc. (NASDAQ:INKT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.